Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium
Background: Stabilized mutant p53 protein (mutp53) is a novel target in epithelial ovarian cancer. Due to aberrant conformation, mutp53 proteins depend on folding support by the Hsp90 chaperone. Hsp90 blockade induces degradation of mutp53, resulting in tumor cell cytotoxicity and increased sensitiv...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00832/full |
| _version_ | 1819007092735868928 |
|---|---|
| author | Isabelle Ray-Coquard Ioana Braicu Regina Berger Sven Mahner Jalid Sehouli Eric Pujade-Lauraine Philippe Alexandre Cassier Ute Martha Moll Hanno Ulmer Karin Leunen Alain Gustave Zeimet Christian Marth Ignace Vergote Nicole Concin |
| author_facet | Isabelle Ray-Coquard Ioana Braicu Regina Berger Sven Mahner Jalid Sehouli Eric Pujade-Lauraine Philippe Alexandre Cassier Ute Martha Moll Hanno Ulmer Karin Leunen Alain Gustave Zeimet Christian Marth Ignace Vergote Nicole Concin |
| author_sort | Isabelle Ray-Coquard |
| collection | DOAJ |
| description | Background: Stabilized mutant p53 protein (mutp53) is a novel target in epithelial ovarian cancer. Due to aberrant conformation, mutp53 proteins depend on folding support by the Hsp90 chaperone. Hsp90 blockade induces degradation of mutp53, resulting in tumor cell cytotoxicity and increased sensitivity to chemotherapeutics. Preclinical synergy of the Hsp90 inhibitor ganetespib combined with paclitaxel provided the rationale for testing the combination in platinum-resistant ovarian cancer (PROC) patients in the GANNET53 trial (NCT02012192).Methods: Eligible patients had high-grade PROC with ≤ 4 prior lines of chemotherapy. Weekly paclitaxel (80 mg/m2) and increasing doses of ganetespib (100, 150 mg/m2) were given i.v. on days 1, 8, 15 in a 28 days cycle until disease progression or unacceptable toxicity. Endpoints were safety and determination of phase II dose. Dose limiting toxicity (DLT) was defined as grade 4 toxicity (with exceptions) occurring in cycles 1&2.Results: Ten patients (median age 59 years; range 43–70) were enrolled. No DLT occurred in cohort 1 (4 patients treated with paclitaxel + ganetespib 100 mg/m2), nor in cohorts 2 and 3 (6 patients treated with paclitaxel + ganetespib 150 mg/m2). The most common adverse event (AE) related to ganetespib was transient grade 1/2 diarrhea (n = 6). Related grade 1/2 AEs in >2 patients included QTc prolongation (n = 4), nausea (n = 3), anemia (n = 3), headache (n = 3), fatigue (n = 3), and dyspnoea (n = 3). Most frequently related grade 3/4 AEs were diarrhea (n = 3) and neutropenia (n = 2). There was 1 death on study due to hemorrhage from a duodenal ulcer. Three patients discontinued study treatment due to serious AEs (digestive hemorrhage n = 1, cardiac failure n = 1, abdominal pain and vomiting n = 1), 6 due to progressive disease, one due to investigator and patient decision. Two patients achieved a partial response (ORR 20%) and 4 patients a stable disease (disease control rate of 60%). Median PFS was 2.9 months (1.6 months in cohort 1 at 100 mg/m2 ganetespib, 5.1 months in cohorts 2+3 at 150 mg/m2 ganetespib).Conclusions: The combination of ganetespib 150 mg/m2 with paclitaxel 80 mg/m2 once weekly for 3 out of 4 weeks was generally well-tolerated with no DLTs, and therefore chosen for the randomized phase II trial. |
| first_indexed | 2024-12-21T00:19:05Z |
| format | Article |
| id | doaj.art-8601cb9f6b384df886c2d55dca630015 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-21T00:19:05Z |
| publishDate | 2019-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-8601cb9f6b384df886c2d55dca6300152022-12-21T19:22:09ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2019-09-01910.3389/fonc.2019.00832458584Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 ConsortiumIsabelle Ray-Coquard0Ioana Braicu1Regina Berger2Sven Mahner3Jalid Sehouli4Eric Pujade-Lauraine5Philippe Alexandre Cassier6Ute Martha Moll7Hanno Ulmer8Karin Leunen9Alain Gustave Zeimet10Christian Marth11Ignace Vergote12Nicole Concin13Centre Anticancereux Léon Bérard, University Claude Bernard Lyon, GINECO Group, Lyon, FranceDepartment of Gynecology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, NOGGO Group, Berlin, GermanyDepartment of Obstetrics and Gynecology, Medical University of Innsbruck, Austrian AGO, Innsbruck, AustriaDepartment of Gynecology, University Medical Center Hamburg-Eppendorf, AGO, Hamburg, GermanyDepartment of Gynecology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, NOGGO Group, Berlin, GermanyAssistance Publique - Hopitaux De Paris, GINECO Group, Paris, FranceCentre Anticancereux Léon Bérard, Lyon, FranceUniversitätsmedizin Göttingen, Georg-August-Universität Göttingen, Göttingen, GermanyDepartment of Medical Statistics, Informatics and Health Economics, Medical University of Innsbruck, Innsbruck, AustriaDivision of Gynecological Oncology, Department of Gynecology and Obstetrics, Leuven Cancer Institute, Katholieke Universiteit Leuven, Leuven, BelgiumDepartment of Obstetrics and Gynecology, Medical University of Innsbruck, Austrian AGO, Innsbruck, AustriaDepartment of Obstetrics and Gynecology, Medical University of Innsbruck, Austrian AGO, Innsbruck, AustriaDivision of Gynecological Oncology, Department of Gynecology and Obstetrics, Leuven Cancer Institute, Katholieke Universiteit Leuven, Leuven, BelgiumDepartment of Obstetrics and Gynecology, Medical University of Innsbruck, Austrian AGO, Innsbruck, AustriaBackground: Stabilized mutant p53 protein (mutp53) is a novel target in epithelial ovarian cancer. Due to aberrant conformation, mutp53 proteins depend on folding support by the Hsp90 chaperone. Hsp90 blockade induces degradation of mutp53, resulting in tumor cell cytotoxicity and increased sensitivity to chemotherapeutics. Preclinical synergy of the Hsp90 inhibitor ganetespib combined with paclitaxel provided the rationale for testing the combination in platinum-resistant ovarian cancer (PROC) patients in the GANNET53 trial (NCT02012192).Methods: Eligible patients had high-grade PROC with ≤ 4 prior lines of chemotherapy. Weekly paclitaxel (80 mg/m2) and increasing doses of ganetespib (100, 150 mg/m2) were given i.v. on days 1, 8, 15 in a 28 days cycle until disease progression or unacceptable toxicity. Endpoints were safety and determination of phase II dose. Dose limiting toxicity (DLT) was defined as grade 4 toxicity (with exceptions) occurring in cycles 1&2.Results: Ten patients (median age 59 years; range 43–70) were enrolled. No DLT occurred in cohort 1 (4 patients treated with paclitaxel + ganetespib 100 mg/m2), nor in cohorts 2 and 3 (6 patients treated with paclitaxel + ganetespib 150 mg/m2). The most common adverse event (AE) related to ganetespib was transient grade 1/2 diarrhea (n = 6). Related grade 1/2 AEs in >2 patients included QTc prolongation (n = 4), nausea (n = 3), anemia (n = 3), headache (n = 3), fatigue (n = 3), and dyspnoea (n = 3). Most frequently related grade 3/4 AEs were diarrhea (n = 3) and neutropenia (n = 2). There was 1 death on study due to hemorrhage from a duodenal ulcer. Three patients discontinued study treatment due to serious AEs (digestive hemorrhage n = 1, cardiac failure n = 1, abdominal pain and vomiting n = 1), 6 due to progressive disease, one due to investigator and patient decision. Two patients achieved a partial response (ORR 20%) and 4 patients a stable disease (disease control rate of 60%). Median PFS was 2.9 months (1.6 months in cohort 1 at 100 mg/m2 ganetespib, 5.1 months in cohorts 2+3 at 150 mg/m2 ganetespib).Conclusions: The combination of ganetespib 150 mg/m2 with paclitaxel 80 mg/m2 once weekly for 3 out of 4 weeks was generally well-tolerated with no DLTs, and therefore chosen for the randomized phase II trial.https://www.frontiersin.org/article/10.3389/fonc.2019.00832/fullrecurrent ovarian carcinomap53 mutationHsp90 inhibitorsganetespibplatinum-resistance |
| spellingShingle | Isabelle Ray-Coquard Ioana Braicu Regina Berger Sven Mahner Jalid Sehouli Eric Pujade-Lauraine Philippe Alexandre Cassier Ute Martha Moll Hanno Ulmer Karin Leunen Alain Gustave Zeimet Christian Marth Ignace Vergote Nicole Concin Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium Frontiers in Oncology recurrent ovarian carcinoma p53 mutation Hsp90 inhibitors ganetespib platinum-resistance |
| title | Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium |
| title_full | Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium |
| title_fullStr | Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium |
| title_full_unstemmed | Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium |
| title_short | Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium |
| title_sort | part i of gannet53 a european multicenter phase i ii trial of the hsp90 inhibitor ganetespib combined with weekly paclitaxel in women with high grade platinum resistant epithelial ovarian cancer a study of the gannet53 consortium |
| topic | recurrent ovarian carcinoma p53 mutation Hsp90 inhibitors ganetespib platinum-resistance |
| url | https://www.frontiersin.org/article/10.3389/fonc.2019.00832/full |
| work_keys_str_mv | AT isabelleraycoquard partiofgannet53aeuropeanmulticenterphaseiiitrialofthehsp90inhibitorganetespibcombinedwithweeklypaclitaxelinwomenwithhighgradeplatinumresistantepithelialovariancancerastudyofthegannet53consortium AT ioanabraicu partiofgannet53aeuropeanmulticenterphaseiiitrialofthehsp90inhibitorganetespibcombinedwithweeklypaclitaxelinwomenwithhighgradeplatinumresistantepithelialovariancancerastudyofthegannet53consortium AT reginaberger partiofgannet53aeuropeanmulticenterphaseiiitrialofthehsp90inhibitorganetespibcombinedwithweeklypaclitaxelinwomenwithhighgradeplatinumresistantepithelialovariancancerastudyofthegannet53consortium AT svenmahner partiofgannet53aeuropeanmulticenterphaseiiitrialofthehsp90inhibitorganetespibcombinedwithweeklypaclitaxelinwomenwithhighgradeplatinumresistantepithelialovariancancerastudyofthegannet53consortium AT jalidsehouli partiofgannet53aeuropeanmulticenterphaseiiitrialofthehsp90inhibitorganetespibcombinedwithweeklypaclitaxelinwomenwithhighgradeplatinumresistantepithelialovariancancerastudyofthegannet53consortium AT ericpujadelauraine partiofgannet53aeuropeanmulticenterphaseiiitrialofthehsp90inhibitorganetespibcombinedwithweeklypaclitaxelinwomenwithhighgradeplatinumresistantepithelialovariancancerastudyofthegannet53consortium AT philippealexandrecassier partiofgannet53aeuropeanmulticenterphaseiiitrialofthehsp90inhibitorganetespibcombinedwithweeklypaclitaxelinwomenwithhighgradeplatinumresistantepithelialovariancancerastudyofthegannet53consortium AT utemarthamoll partiofgannet53aeuropeanmulticenterphaseiiitrialofthehsp90inhibitorganetespibcombinedwithweeklypaclitaxelinwomenwithhighgradeplatinumresistantepithelialovariancancerastudyofthegannet53consortium AT hannoulmer partiofgannet53aeuropeanmulticenterphaseiiitrialofthehsp90inhibitorganetespibcombinedwithweeklypaclitaxelinwomenwithhighgradeplatinumresistantepithelialovariancancerastudyofthegannet53consortium AT karinleunen partiofgannet53aeuropeanmulticenterphaseiiitrialofthehsp90inhibitorganetespibcombinedwithweeklypaclitaxelinwomenwithhighgradeplatinumresistantepithelialovariancancerastudyofthegannet53consortium AT alaingustavezeimet partiofgannet53aeuropeanmulticenterphaseiiitrialofthehsp90inhibitorganetespibcombinedwithweeklypaclitaxelinwomenwithhighgradeplatinumresistantepithelialovariancancerastudyofthegannet53consortium AT christianmarth partiofgannet53aeuropeanmulticenterphaseiiitrialofthehsp90inhibitorganetespibcombinedwithweeklypaclitaxelinwomenwithhighgradeplatinumresistantepithelialovariancancerastudyofthegannet53consortium AT ignacevergote partiofgannet53aeuropeanmulticenterphaseiiitrialofthehsp90inhibitorganetespibcombinedwithweeklypaclitaxelinwomenwithhighgradeplatinumresistantepithelialovariancancerastudyofthegannet53consortium AT nicoleconcin partiofgannet53aeuropeanmulticenterphaseiiitrialofthehsp90inhibitorganetespibcombinedwithweeklypaclitaxelinwomenwithhighgradeplatinumresistantepithelialovariancancerastudyofthegannet53consortium |